DK1276752T3 - Fremgangsmåde til vurdering af risikoen for, at en person udvikler vaskulære komplikationer - Google Patents

Fremgangsmåde til vurdering af risikoen for, at en person udvikler vaskulære komplikationer

Info

Publication number
DK1276752T3
DK1276752T3 DK01925836.7T DK01925836T DK1276752T3 DK 1276752 T3 DK1276752 T3 DK 1276752T3 DK 01925836 T DK01925836 T DK 01925836T DK 1276752 T3 DK1276752 T3 DK 1276752T3
Authority
DK
Denmark
Prior art keywords
risk
vascular complications
assessing
procedure
developing vascular
Prior art date
Application number
DK01925836.7T
Other languages
English (en)
Inventor
Andrew P Levy
Original Assignee
Rappaport Family Inst For Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/556,469 external-priority patent/US6251608B1/en
Application filed by Rappaport Family Inst For Res filed Critical Rappaport Family Inst For Res
Application granted granted Critical
Publication of DK1276752T3 publication Critical patent/DK1276752T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6862—Ligase chain reaction [LCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Financial Or Insurance-Related Operations Such As Payment And Settlement (AREA)
  • Eye Examination Apparatus (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
DK01925836.7T 2000-04-20 2001-04-19 Fremgangsmåde til vurdering af risikoen for, at en person udvikler vaskulære komplikationer DK1276752T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/556,469 US6251608B1 (en) 2000-04-20 2000-04-20 Method of determining a potential of a hyperglycemic patients of developing vascular complications
US23769600P 2000-10-05 2000-10-05
US09/688,121 US6599702B1 (en) 2000-04-20 2000-10-16 Method of evaluating a risk of a subject of developing vascular complications
PCT/IL2001/000368 WO2001080711A2 (en) 2000-04-20 2001-04-19 Method of evaluating a risk of a subject of developing vascular complications

Publications (1)

Publication Number Publication Date
DK1276752T3 true DK1276752T3 (da) 2011-02-07

Family

ID=27399009

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01925836.7T DK1276752T3 (da) 2000-04-20 2001-04-19 Fremgangsmåde til vurdering af risikoen for, at en person udvikler vaskulære komplikationer

Country Status (6)

Country Link
US (1) US6599702B1 (da)
EP (1) EP1276752B1 (da)
AT (1) ATE486085T1 (da)
AU (1) AU5251101A (da)
DK (1) DK1276752T3 (da)
WO (1) WO2001080711A2 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608393B2 (en) * 2000-04-20 2009-10-27 Rappaport Family Institute For Research In The Medical Sciences Methods of predicting a benefit of antioxidant therapy for prevention of cardiovascular disease in hyperglycemic patients
CA2512499A1 (en) * 2003-01-02 2004-07-22 Rappaport Family Institute For Research In The Medical Sciences Methods of predicting a benefit of antioxidant therapy for prevention of cardiovascular disease in hyperglycemic patients
US8280805B1 (en) 2006-01-10 2012-10-02 Sas Institute Inc. Computer-implemented risk evaluation systems and methods
US7610257B1 (en) * 2006-01-10 2009-10-27 Sas Institute Inc. Computer-implemented risk evaluation systems and methods
US7912773B1 (en) * 2006-03-24 2011-03-22 Sas Institute Inc. Computer-implemented data storage systems and methods for use with predictive model systems
WO2008143883A1 (en) * 2007-05-14 2008-11-27 Synvista Therapeutics, Inc. Use of haptoglobin genotyping in diagnosis and treatment of defective reverse cholesterol transport (rct)
WO2008153906A1 (en) * 2007-06-06 2008-12-18 Rappaport Family Institute For Research In The Medical Sciences Haptoglobin genotyping for prognosis and treatment of chronic vasospasm following subarachnoid hemorrhage (sah)
US8515862B2 (en) * 2008-05-29 2013-08-20 Sas Institute Inc. Computer-implemented systems and methods for integrated model validation for compliance and credit risk
EP2347004B1 (en) 2008-06-13 2016-08-10 Rappaport Family Institute for Research in the Medical Sciences Reagents and methods for detecting the polymorphic protein haptoglobin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1010935A7 (nl) * 1997-02-19 1999-03-02 Delanghe Joris Richard Siegfri Fenotypering van humaan haptoglobine in serum of plasma door middel van quantitatieve agglutinatie met streptococcus antigenen.
US6251608B1 (en) * 2000-04-20 2001-06-26 Technion Research & Development Foundation, Ltd. Method of determining a potential of a hyperglycemic patients of developing vascular complications

Also Published As

Publication number Publication date
WO2001080711A3 (en) 2002-03-28
US6599702B1 (en) 2003-07-29
WO2001080711A2 (en) 2001-11-01
EP1276752A2 (en) 2003-01-22
AU5251101A (en) 2001-11-07
EP1276752B1 (en) 2010-10-27
ATE486085T1 (de) 2010-11-15
EP1276752A4 (en) 2007-04-25

Similar Documents

Publication Publication Date Title
AU3084802A (en) Inflammatory markers as tools in the detection and prevention of diabetes mellitus and as tools to aid in the selection of agents to be used for the prevention and treatment of diabetes
WO2006036943A3 (en) Determination of molecular age by detection of ink4a/arf expression
DK1003501T3 (da) Anvendelse af et middel til reduktion af risikoen for kardiovaskulær sygdom
ATE440538T1 (de) System oder verfahren zur beurteilung der peripheren blutzirkulation einer person
DE60228557D1 (de) Candida-nachweis
DE60138829D1 (de) Verfahren zur unterscheidung des reizkolons von der entzündlichen darmerkrankung (inflammatory bowel disease, ibd) und zur überwachung von patienten mit ibd unter verwendung von endogenem gesamt-lactoferrin als marker
TW200719866A (en) Method of measuring blood circulation velocity by controlling breath
DK1276752T3 (da) Fremgangsmåde til vurdering af risikoen for, at en person udvikler vaskulære komplikationer
DE602005019890D1 (de) Chinazolinderivate und ihre verwendung bei der behandlung von thrombocythämie
DK0749582T3 (da) Fremgangsmåde til diagnosticering af præeklampsi
DK2298362T3 (da) Reagerende paramagnetiske kontrastmidler til magnetresonansbilledteknik
DE60124975D1 (de) Automatischer apparat zum messen von wassertoxizität
DK1800134T3 (da) Fremgangsmåde til diagnosticering og behandling af Chron's sygdom
WO2006113880A3 (en) Intact igfbp-3 as a colon cancer risk factor in patients with inflammatory bowel disease
ATE426675T1 (de) Differenzialdiagnostik mit hepcidin
WO2001080712A3 (en) Method of determining a risk of hyperglycemic patients of developing a cardiovascular disease
ATE383564T1 (de) Optisches interferometer
ATE546548T1 (de) Verfahren zur prognose des nutzens einer antioxidationshemmenden therapie zur vorbeugung von herz-kreislauf-erkrankungen bei hyperglykämischen patienten
DE60332257D1 (de) Verfahren zur bestimmung von anfälligkeit einer person zur infektion
DK1558929T3 (da) Kvantificering af stresseksponering
KR970702928A (ko) 크립토콕쿠스증에 대해 위험이 큰 면역약화된 환자의 동정 방법(Method to identify immunocompromised patients at high risk for cryptococcosis)
NO20051602L (no) Assosiering av H2 haplotypen av P2Y12 reseptoren med en oket risiko for trombose og perifer arteriell sykdom
RU2002111522A (ru) Способ оценки восстановления слуховой функции в остром периоде сенсоневральной тугоухости
RU2004121380A (ru) Способ оценки функции щитовидной железы
UA34205A (uk) Спосіб визначення захисної функції плаценти